Abstract
The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the p53 tumor suppressor, directly contributing to the development and progression of many tumors harboring wild type p53. Antagonizing MDM2 and MDMX to activate the p53 pathway has thus become an attractive new strategy for anticancer drug design. Several different classes of MDM2 and MDMX antagonists have been reported, including low molecular weight compounds, small peptides, miniature proteins, and peptidomimetics. This review aims to summarize the latest progress in the design of peptide activators of the p53 tumor suppressor.
Keywords: MDM2, MDMX, p53, D-peptide, peptidomimetics, mini-protein, proteins, helical, Hairpin, H-bonded, Nutlin-3, antagonists, D-enantiomer, hydrophobic
Current Pharmaceutical Design
Title: Peptide Activators of the p53 Tumor Suppressor
Volume: 17 Issue: 6
Author(s): Changyou Zhan and Wuyuan Lu
Affiliation:
Keywords: MDM2, MDMX, p53, D-peptide, peptidomimetics, mini-protein, proteins, helical, Hairpin, H-bonded, Nutlin-3, antagonists, D-enantiomer, hydrophobic
Abstract: The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the p53 tumor suppressor, directly contributing to the development and progression of many tumors harboring wild type p53. Antagonizing MDM2 and MDMX to activate the p53 pathway has thus become an attractive new strategy for anticancer drug design. Several different classes of MDM2 and MDMX antagonists have been reported, including low molecular weight compounds, small peptides, miniature proteins, and peptidomimetics. This review aims to summarize the latest progress in the design of peptide activators of the p53 tumor suppressor.
Export Options
About this article
Cite this article as:
Zhan Changyou and Lu Wuyuan, Peptide Activators of the p53 Tumor Suppressor, Current Pharmaceutical Design 2011; 17 (6) . https://dx.doi.org/10.2174/138161211795222577
DOI https://dx.doi.org/10.2174/138161211795222577 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indole Compounds Against Breast Cancer: Recent Developments
Current Drug Targets Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Neuropeptide-Derived Antimicrobial Peptides from Invertebrates for Biomedical Applications
Current Medicinal Chemistry Computational Methods for DNA-binding Protein and Binding Residue Prediction
Protein & Peptide Letters Recent Progress in Stimuli-Responsive Intelligent Nano Scale Drug Delivery Systems: A Special Focus Towards pH-Sensitive Systems
Current Drug Targets Modulation of Cellular Function by TAT Mediated Transduction of Full Length Proteins
Current Protein & Peptide Science Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Adhesion Mechanisms of the Lyme Disease Spirochete, Borrelia burgdorferi
Current Drug Targets - Infectious Disorders Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Small-Molecule Inhibitors of Bcl-2 Family Proteins as Therapeutic Agents in Cancer
Recent Patents on Anti-Cancer Drug Discovery Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer
Current Molecular Medicine Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model
Clinical Cancer Drugs Computational Studies on Translocator Protein (TSPO) and its Ligands
Current Topics in Medicinal Chemistry Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery